Drug Hunter Journal Club: March 2023

This summary of September's major clinical updates features FDA approvals, drug withdrawals, anticipated regulatory decisions, notable trial results, new NDA submissions, clinical trial setbacks, and the initiation of new clinical trials.

Here’s a rundown of August’s key clinical developments, including FDA approvals, potential upcoming approvals, notable trial readouts, new NDA submissions, and pipeline realignments.

GSK and Roche strengthened their pipelines by forming groundbreaking collaborations that target neurodegenerative diseases and transcription factors, respectively. Meanwhile, Pep2Tango Therapeutics introduced a novel obesity treatment approach, and Amgen faced scrutiny over emerging data on its obesity drug candidate MariTide. This roundup covers the details behind these headlines.

In this article, you'll find a curated selection of >70 molecules from August that piqued our interest, highlights of some of our favorites, and explanations of why they're worth watching.

This summary of major clinical updates from November 2024 covers FDA approvals, the initiation of new clinical trials, notable trial outcomes for key drug candidates, and news on paused and discontinued trials and programs.